Submission based on favorable efficacy and safety results from Phase 3 VALOR trial
Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme...
The spring of 2026 arrived with a vibrant bloom of flowers and an unprecedented, crawling wave of arachnids. Recent social media feeds resemble scenes from a horror movie, a shared experience for millions...
NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact...
NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to...
NEW YORK , April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact...
NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to...
NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact...
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational...
VIENNA, Austria , March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive...